{"id":"W4401436077","doi":"10.1093/bjd/ljae266.005","title":"619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Eczema Area and Severity Index; Medicine; Atopic dermatitis; Adverse effect; Placebo; Clinical endpoint; Concomitant; Randomized controlled trial; Randomization; Body surface area; Internal medicine; Potency; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001829916,0.001032974,0.002442534,0.0003437962,0.0004601223,0.0008164533,0.0005717847,0.001117803,0.006261699],"category_scores_gemma":[0.0009829918,0.0004993501,0.001657851,0.000269132,0.0008576163,0.0008264021,0.0003044858,0.001988923,0.0006879351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003990057,"about_ca_system_score_gemma":0.0009550733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003319372,"about_ca_topic_score_gemma":0.001001398,"domain_scores_codex":[0.9994627,0.0002423196,0.00005196564,0.00008195912,0.00005141849,0.0001096746],"domain_scores_gemma":[0.9992571,0.0001847903,0.000163608,0.00006490307,0.00006044055,0.0002691371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9478665,0.01867051,0.00169976,0.0006059455,0.0005228312,0.00007658396,0.00004793449,0.0001390829,0.009676128,0.00008226586,0.0006569258,0.01995549],"study_design_scores_gemma":[0.8257744,0.169092,0.003413363,0.00002527482,0.0002471762,0.00006130561,0.00001896284,0.0001939492,0.0006873667,0.00004620812,0.0004305911,0.00000935214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933667,0.002456001,0.0002789674,0.0003034491,0.0002171622,0.002042574,0.0004011367,0.00006829078,0.000865806],"genre_scores_gemma":[0.9922701,0.001460524,0.001046828,0.0007068534,0.0003841382,0.002162213,0.000488787,0.00001424617,0.001466251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006261699,"threshold_uncertainty_score":0.02094752,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01450607466599031,"score_gpt":0.3350723834330195,"score_spread":0.3205663087670292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}